Mrinalini Dey DrMiniDey
11 months ago
#1748 Higher air pollution, esp PM2.5, linked to ⬆️RA disease activity and more flares in >1000 Korean patients. Each rise in PM2.5 significantly boosted DAS28, CDAI & joint counts.
Does cleaner air mean calmer joints?
@RheumNow #ACR25
David Liew drdavidliew
11 months ago
There’s all sorts of products out there. Who knows, ‘Reuma King’ or ‘Contra Reumas’ might do something, but that’s probably all the fraudulent hidden dexamethasone inside…
Beware+++
#ACR25 FDA Update @RheumNow https://t.co/rco4wTXBjO
Antoni Chan MD (Prof) synovialjoints
11 months ago
Making sense of machine learning. Key slides on Discriminative AI vs Generative AI. Liubov Arbeeva @RheumNow #ACR25 https://t.co/Xli1mSTVQf
sheila RHEUMarampa
11 months ago
Dr. John Stone on IgG4RD
⬆️ common in males
⬆️internal organ involvement
🔸Mimics cancer
🔸Indolence makes it dangerous —-> organ complications
Diagnosis highly dependent on the rheumatologist based on clinical features, serologies, imaging & pathological data
#ACR25 @Rheumnow https://t.co/St4EbA7Dcj
Aurelie Najm AurelieRheumo
11 months ago
US Electronic Health Record cohort 2000+pts
Incidence Heart Failure over 10 yrs 6.8%
HF asso w/
Older
Male
Lower eGFR
Hypertensive medication
Diabetes
TTMTS MTX, TNFi
Higher CRP
Probably surrogates for High Disease Activity...
How do we detect it?
Maybe not by using the https://t.co/s9SjEyk3WF
David Liew drdavidliew
11 months ago
@RheumNow Plus a heap more biosimilars have broken through in the US in the last year. It feels the biosimilar era is now here stateside, too.
#ACR25 FDA Update @RheumNow https://t.co/9RiyhbKXU4
David Liew drdavidliew
11 months ago
@RheumNow Obinutuzumab for lupus nephritis was a very recent FDA addition two weeks ago, and we’ll play catch-up with the hematologists to get familiar with it, including its safety profile
#ACR25 FDA Update @RheumNow https://t.co/h6bf4roGzB
David Liew drdavidliew
11 months ago
Perhaps it was my ignorance, but a FDA-approved therapy for fibromyalgia was not on my 2025 bingo card.
We’re not exactly overwhelmed with proven options for FM, the unmet need is so great, so the more, the better.
#ACR25 FDA session @RheumNow https://t.co/wwWijl3IyW
Richard Conway RichardPAConway
11 months ago
Cooper et al. FAERS based analysis of adverse events with avacopan.3658 patients on avacopan, 30 million overall. DILI seems to be the big concern, with Reporting Odds Ratio of >17. @RheumNow #ACR25 Abstr#2519 https://t.co/1LoDvRHkqa
David Liew drdavidliew
11 months ago
@US_FDA rheumatology approvals, 2025
#ACR25 @RheumNow https://t.co/uVLWqBx45m
Janet Pope Janetbirdope
11 months ago
IgG4 - Rare but Rx
Several studies #ACR25 @ACRheum were presented
Outcome measures
Rx
#steroids
#CD19 mAb #Inebilizumab
👍+RCT reduction of flares
BTKi
#Rilzabrutinib
#Zanubrutinib
#JAKi
+RCT of #tofacitinib +steroids vs pred
@ACRheum @RheumNow #ACR25
1163 LB02 0239 1172 https://t.co/xC3wgaN9bk
Jiha Lee JihaRheum
11 months ago
Sjögren’s, decoded by Ab -->ESSDAI domains:
• anti-SSA → glandular
• anti-Ro52 / SCL70 → biologic activity
• anti-nucleosome → pulmonary
• anti-histone → pulmonary + cutaneous
Distinct serologic–ESSDAI patterns may guide monitoring and management
@RheumNow #ACR25 A#2295
Md Yuzaiful Md Yusof Yuz6Yusof
11 months ago
#ACR25 Abstr#LB14 Deep blood & tissue depletion are not just confined to CAR-T. Exploratory analysis of REGENCY showed Obinutuzumab induced near-complete depletion & significantly reduced plasma in kidney tissue vs PBO @RheumNow https://t.co/r1danWBM7D
Antoni Chan MD (Prof) synovialjoints
11 months ago
In PsA, a predictive model using routine labs (NLR, LMR, ESR, C3, baseline DAPSA) identified TNFi responders with 100% sensitivity and 0.861 AUC. Supports biomarker-driven personalization of PsA treatment. Abstract#2371 @RheumNow #ACR25 https://t.co/lojQFfWsJi
